Synthesis and biological evaluation of 2',3'-didehydro-2',3'-dideoxy-9-deazaguanosine, a monophosphate prodrug and two analogues, 2',3'-dideoxy-9-deazaguanosine and 2',3'-didehydro-2',3'-dideoxy-9-deazainosine. 2005

Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
Department of Pharmacology and Developmental Therapeutics Program, Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA.

2',3'-Didehydro-2',3'-dideoxy-9-deazaguanosine (1), its monophosphate prodrug (2), and two analogues, 2',3'-dideoxy-9-deazaguanosine (3) and 2',3'-didehydro-2',3'-dideoxy-9-deazainosine (4), have been synthesized from benzoylated 9-deazaguanosine (5). Basic hydrolysis of 5, selective protection of the 2-amino and 5'-hydroxy functions with isobutyryl and silyl groups, respectively, followed by reaction with thiocarbonyldiimidazole gave the cyclic thiocarbonate, which, upon reaction with triethyl phosphite, followed by deprotection, afforded 1. Treatment of 1 with phenyl methoxyalaninylphosphochloridate and N-methylimidazole gave 2. Catalytic hydrogenation of 1 gave 3. Hydrodediazoniation of 1 with tert-butyl nitrite and tris(trimethylsilyl)silane gave 4. Compounds 1-4 were found to be inactive against the human immunodeficiency virus and exhibited minimal to no cytotoxic activity against the L1210 leukemia, CCRF-CEM lymphoblastic leukemia, and B16F10 melanoma in vitro.

UI MeSH Term Description Entries
D007288 Inosine A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D003849 Deoxyguanosine A nucleoside consisting of the base guanine and the sugar deoxyribose.
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D019337 Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES. Blood Cancer,Hematologic Malignancies,Hematopoietic Neoplasms,Hematologic Malignancy,Hematological Malignancies,Hematological Neoplasms,Hematopoietic Malignancies,Malignancies, Hematologic,Malignancy, Hematologic,Neoplasms, Hematologic,Neoplasms, Hematopoietic,Blood Cancers,Cancer, Blood,Hematologic Neoplasm,Hematological Malignancy,Hematological Neoplasm,Hematopoietic Malignancy,Hematopoietic Neoplasm,Malignancy, Hematological,Malignancy, Hematopoietic,Neoplasm, Hematologic,Neoplasm, Hematological,Neoplasm, Hematopoietic

Related Publications

Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
July 1998, Bioorganic & medicinal chemistry letters,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
March 2009, Bioorganic & medicinal chemistry,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
January 2006, Antiviral chemistry & chemotherapy,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
January 1999, Nucleosides & nucleotides,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
October 2010, Bioorganic & medicinal chemistry,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
January 2001, Nucleosides, nucleotides & nucleic acids,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
January 2001, Nucleic acids research. Supplement (2001),
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
October 2010, Bioorganic & medicinal chemistry letters,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
August 1999, Journal of medicinal chemistry,
Mao-Chin Liu, and Mei-Zhen Luo, and Diane E Mozdziesz, and Ginger E Dutschman, and Elizabeth A Gullen, and Yung-Chi Cheng, and Alan C Sartorelli
August 1994, Acta crystallographica. Section C, Crystal structure communications,
Copied contents to your clipboard!